Despite the anticipation of a major announcement at the 61st Commission on Narcotic Drugs relating to the international scheduling of cannabis, no announcement came from the World Health Organization (WHO) today. Many expected the WHO to issue a recommendation on its findings of the first ever critical review of cannabis, however the WHO delayed its recommendation saying that it needed more time to review its findings.
“This decision to withhold the results of the critical review of cannabis appears to be politically motivated,” Michael Krawitz, a U.S. Air Force veteran and legalization advocate who has pushed for international reform, said in a press release.
“The WHO has been answering many questions about cannabis legalization, which is not within their mandate. I hope the WHO shows courage and stands behind their work on cannabis, findings we expect to be positive based upon recent WHO statements and their other actions today.”
The WHO has not published a date where it expects to release its recommendations, but nations are expected to vote on the rescheduling of cannabis in March of 2019. However, without the recommendation from WHO this vote may be pushed back to a later date.
ASA has played and continues to play an important role in the ongoing discussions on cannabis policy on the international level, and will continue to keep you updated about changes that could impact U.S. law.
By David Mangone
David Mangone Esq., Director of Government Affairs | Legislative Counsel
David Mangone brings both congressional and professional legal experience to his role at Americans for Safe Access. Having served as a Legislative Fellow on Capitol Hill and as an attorney in both South Carolina and D.C., he has appreciation for the conflict of federal and state laws that patients struggle with every day. Focusing on statutory interpretation and Congressional advocacy, David believes the best way to help patients in need of treatment is engage lawmakers and encourage robust regulatory change.